EW241220P95000
- 0.00
- 0.000.00%
Edwards Lifesciences Newsroom
RBC Capital Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $80
Hold Rating Maintained on Edwards Lifesciences Despite Positive SAPIEN 3 Ultra RESILIA Valve Data
Piper Sandler Reaffirms Their Hold Rating on Edwards Lifesciences (EW)
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $81 From $80, Maintains Buy Rating
TD Cowen Maintains Edwards Lifesciences(EW.US) With Hold Rating, Maintains Target Price $70
Piper Sandler Maintains Edwards Lifesciences(EW.US) With Hold Rating, Maintains Target Price $70
Oppenheimer Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $90
A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $70 to $90
A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $70 to $90
Daiwa Downgrades Edwards Lifesciences to Neutral From Outperform, Price Target Is $72
A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $70 to $90
Bernstein Upgrades Edwards Lifesciences(EW.US) to Hold Rating
Barclays Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $85
Barclays Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $85
Strong Growth and Promising Outlook: Buy Rating for Edwards Lifesciences
A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $73 to $90
Edwards Lifesciences Is Maintained at Neutral by Piper Sandler
Edwards Lifesciences Price Target Cut to $70.00/Share From $71.00 by Truist Securities
Redburn Atlantic Adjusts Price Target on Edwards Lifesciences to $80 From $88
A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $75 to $90